Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease.

Annals of neurology·2026
Same author

Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial).

International journal of cancer·2026
Same author

Retinal structural alterations in Parkinson's disease: association between temporal optic disc thickening and visual hallucinations.

Neurodegenerative disease management·2026
Same author

Marked Improvement of Sialorrhea with Safinamide in Parkinson's Disease: A Case Series.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Subthalamic nucleus deep brain stimulation and associations with attention and processing speed in Parkinson's disease.

Experimental brain research·2026
Same author

Clinical correlates of global and axial levodopa response in Parkinson's disease.

Neurodegenerative disease management·2026

Related Experiment Video

Updated: May 26, 2026

Measuring Constipation in a Drosophila Model of Parkinson's Disease
03:20

Measuring Constipation in a Drosophila Model of Parkinson's Disease

Published on: September 22, 2023

Functional bowel disorders in idiopathic Parkinson's disease: a Rome IV-based controlled study.

Zehra Yavuz1, Merve Uzun1, Turay Mutlu1

  • 1Department of Neurology, Ankara Etlik City Hospital, Ankara, Turkey.

Neurodegenerative Disease Management
|May 25, 2026
PubMed
Summary

Functional bowel disorders (FBDs) are common in idiopathic Parkinson's disease (iPD), but prevalence did not differ in this study. FBDs were linked to increased non-motor symptoms and reduced quality of life in iPD patients.

Keywords:
Idiopathic Parkinson’s diseaseRome IV criteriafunctional bowel disordersgastrointestinal quality of lifenon-motor symptoms

More Related Videos

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease
05:17

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

Published on: November 28, 2025

Related Experiment Videos

Last Updated: May 26, 2026

Measuring Constipation in a Drosophila Model of Parkinson's Disease
03:20

Measuring Constipation in a Drosophila Model of Parkinson's Disease

Published on: September 22, 2023

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease
05:17

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

Published on: November 28, 2025

Area of Science:

  • Neurology
  • Gastroenterology
  • Clinical Research

Background:

  • Functional gastrointestinal disorders (FGIDs) are recognized as part of the non-motor spectrum in idiopathic Parkinson's disease (iPD).
  • The specific prevalence and clinical significance of Rome IV-defined functional bowel disorders (FBDs) in iPD patients are not well-established.
  • Understanding FBDs in iPD is crucial for managing the non-motor symptoms and improving patient quality of life.

Purpose of the Study:

  • To evaluate the prevalence of Rome IV-defined FBDs in patients with idiopathic Parkinson's disease (iPD).
  • To identify correlations between FBDs and non-motor symptoms, mood, and quality of life in iPD.
  • To compare FBD prevalence in iPD patients with a control group enriched for FGIDs.

Main Methods:

  • A cross-sectional study involving 64 iPD patients and 64 controls without neurological disease, all assessed for Rome IV-defined FGIDs.
  • Utilized the Rome IV Diagnostic Questionnaire for FGID assessment.
  • Employed validated scales including NMSS, Hamilton scales, PDQ-39, and GIQLI to evaluate non-motor symptoms, mood, and quality of life, followed by multivariable analyses.

Main Results:

  • No significant difference in FBD prevalence was observed between iPD patients (20.3%) and the FGID-enriched control group (21.9%).
  • Within the iPD cohort, FBD positivity correlated with poorer quality of life (PDQ-39 scores) and a higher burden of non-motor symptoms, particularly affecting attention/memory and sexual function.
  • Anxiety severity showed a negative association with quality of life as measured by the GIQLI.

Conclusions:

  • Despite similar prevalence to controls, FBDs in iPD are associated with a greater non-motor symptom burden and diminished quality of life.
  • These findings suggest FBDs may reflect variations in the non-motor phenotype of iPD rather than being a direct risk factor.
  • Caution is advised in interpretation due to potential control selection bias and demographic imbalances in the study cohort.